Publication Name	World Journal of Cardiology
Manuscript ID	12832
Country	Greece

Received	2014-07-27 17:35
Peer-Review Started	2014-07-28 18:25
To Make the First Decision	2014-08-14 14:48
Return for Revision	2014-08-18 12:57
Revised	2014-08-31 19:18
Second Decision	2014-11-12 14:12
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2014-11-19 10:46
Articles in Press	2014-11-19 10:46
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-02-07 20:34
Publish the Manuscript Online	2015-02-11 19:21

ISSN	1949-8462 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Cardiac & Cardiovascular Systems
Manuscript Type	Minireviews
Article Title	Flecainide: Current status and perspectives in arrhythmia management
Manuscript Source	Unsolicited Manuscript
All Author List	George K Andrikopoulos, Sokratis Pastromas and Stylianos Tzeis
Funding Agency and Grant Number
Corresponding Author	George K Andrikopoulos, MD, PhD, Director of Cardiology Department, Henry Dunant Hospital, Mesogeion ave 107, Athens, 11526 Attica, Greece. andrikop@hotmail.com
Key Words	Flecainide; Class IC antiarrhythmic drugs; Atrial fibrillation; Ventricular tachycardia; Proarrhythmia
Core Tip	Flecainide acetate is recommended as one of the first line antiarrhythmic drugs in patients with atrial fibrillation and/or supraventricular tachycardias for the restoration and maintance of sinus rhythm. Based on the Cardiac Arrhythmia Suppression Trial study results, flecainide is contraindicated for patients with structural heart disease due to high proarrhythmic risk. Recent data support the role of flecainide in preventing ventricular tachyarrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia associated both with ryanodine receptor and calsequestrin mutations.
Publish Date	2015-02-11 19:21
Citation	Andrikopoulos GK, Pastromas S, Tzeis S. Flecainide: Current status and perspectives in arrhythmia management. World J Cardiol 2015; 7(2): 76-85
URL	http://www.wjgnet.com/1949-8462/full/v7/i2/76.htm
DOI	http://dx.doi.org/10.4330/wjc.v7.i2.76

Full Article (PDF)	WJC-7-76.pdf
Full Article (Word)	WJC-7-76.doc
Manuscript File	12832-Review.docx
Answering Reviewers	12832-Answering reviewers.pdf
Copyright License Agreement	12832-Copyright assignment.pdf
Peer-review Report	12832-Peer review(s).pdf
Scientific Misconduct Check	12832-CrossCheck.jpg
Scientific Editor Work List	12832-Scientific editor work list.pdf